Company · CIK 1880438
AN2 Therapeutics, Inc.
| CIK | 1880438 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2834 — Pharmaceutical Preparations |
| Incorporated in | DE |
| Business address | CA |
| Listed | ANTX (Nasdaq) |
| First annual or quarterly report | 2022-05-10 |
Offerings
3 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-294956 | 2026-04-09 | 2026-04-20 | 3 | |
| 333-271174 | 2023-04-06 | 2023-08-16 | 4 | |
| 333-263295 | 2022-03-04 | 2022-03-28 | 4 |
Filings
12| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2026-04-20 | EFFECTDeclared effective | 333-294956 | 9999999995-26-001256 |
| 2026-04-20 | 424B5Shelf takedown | 333-294956 | 0001193125-26-164095 |
| 2026-04-09 | S-3Shelf registered | 333-294956 | 0001193125-26-149869 |
| 2023-08-16 | 424B5Shelf takedown | 333-271174 | 0001193125-23-214364 |
| 2023-04-14 | 424B5Shelf takedown | 333-271174 | 0001193125-23-100832 |
| 2023-04-13 | EFFECTDeclared effective | 333-271174 | 9999999995-23-000930 |
| 2023-04-06 | S-3Shelf registered | 333-271174 | 0001193125-23-094152 |
| 2022-03-28 | 424B4Final prospectus | 333-263295 | 0001193125-22-085459 |
| 2022-03-24 | EFFECTDeclared effective | 333-263295 | 9999999995-22-000716 |
| 2022-03-21 | S-1/AAmendment | 333-263295 | 0001193125-22-080012 |
| 2022-03-04 | S-1Registration filed | 333-263295 | 0001193125-22-066048 |
| 2021-09-24 | DRSDraft made public | 377-05527 | 0000950123-21-012609 |